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Dermatitisherpetiformis(DH)isanautoimmunity-driveninﬂammatoryblisteringdermatosisassociatedwithagluten-dependent
enteropathy. Tissue transglutaminase (tTG) and nonapeptides of gliadin (npG) are considered in its pathomechanism/diagnostics.
Here, the diagnostic accuracy of anti-tTG/anti-npG IgA ELISAs in Slavic DH patients with active skin rash was assessed through
creating receiver operating characteristic (ROC) curves, determining cutoﬀ values, and calculating correlations between levels of
anti-tTG/anti-npG IgA in DH, IgA/neutrophil-mediated non-DH patients and healthy persons. Altogether, sera from 80 Slavic
individuals were examined. There were negligible diﬀerences between cutoﬀ points obtained by the ELISAs manufacturer and
those in this study. There were statistically signiﬁcant correlations between levels of anti-tTG/anti-npG IgA in both DH group and
the group of IgA/neutrophil-mediated non-DH dermatoses. There was no such correlation in healthy controls. It seems that IgA
autoantibodies to tTG and npG in the IgA/neutrophil-mediated DH are produced in the coordinated way implying their causal
relationship.
1.Introduction
Dermatitis herpetiformis (DH) is a chronic, IgA-mediated,
inﬂammatory dermatosis with intense itching and polymor-
phic eruption undergoing the spatial-temporal evolution
[1]. In its pathomechanism, the role is played by both
genetic and environmental factors. Thus, familial occurrence
is sometimes observed [2]. It is universally thought that
DH is associated with gluten-sensitive enteropathy (GSE),
being a cutaneous manifestation of celiac disease (CD) [3].
These diseases are caused by an immune reaction to proline-
rich gliadin, a prolamin (gluten protein) found in wheat
[4]. However, the trigger/triggers of pathological antigliadin
autoimmune response in DH and relationship between CD
and DH still remain inadequately understood. Some studies
indicated epidemiologic trends of increasing incidence of
CD.DHisalsoanimportantmedicalissuedemandinghighly
eﬃcient medical and social services. DH is characterized
by cutaneous microgranular IgA deposits in the dermal
papillae (microgranular and ﬁbrillar deposits are sometimes
seen there) and/or along the dermal-epidermal junction [1];
however, interesting issue is which IgA subclass is dominant
in cutaneous deposits. In humans, IgA1 is a predominant
subclass in the sera, and IgA2 prevails in mucosal secre-
tions of the colon [1]. Immunoﬂuorescence analysis with
monoclonal antibodies revealed that IgA1 without IgA2 was
foundinthecutaneousdepositsinallfourpatientsexamined
in an early study [5]. It was therefore speculated that both
IgA1 and IgA2 may be produced in the pathologic gut-
associated lymphoid tissue, but only IgA1 is involved in2 The Scientiﬁc World Journal
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Figure 1:(a)MicrogranularandﬁbrillarIgA1depositsatdermalpapillaeinDIFinayoungmanwithDH(originalmagniﬁcation ×400).(b)
Neutrophil elastase deposits in immunohistochemistry in lesional skin in a middle-aged woman with DH (original magniﬁcation, ×200).
the production of cutaneous lesions [5]. Still, there are newer
data that both IgA1 and IgA2 are forming IgA cutaneous
deposits in DH, although IgA1 (Figure 1(a)) predominates
[1, 6]. In the development of DH, important is the accumu-
lationofactivated(neutrophilelastase-secreting)neutrophils
(Figure 1(b)) that are forming microabscesses in the dermal
papillae with subsequent formation of microvesicles and
ﬁnally subepidermal (intralamina lucida) blisters [7]. Main
autoantigens in DH are enzymes of the transglutaminase
family [8, 9]: epidermal transglutaminase (eTG) and closely
related tissue transglutaminase (tTG). They are considered
to be autoantigens plausibly recognized by principally IgA1
autoantibodies in this disease [10]. Recently, the role of
nonapeptides of gliadin (npG) in pathomechanism of DH
is considered [11]. Further, there are ﬁndings indicating
that antibodies against deamidated synthetic gliadin-derived
peptides are the most reliable tool in order to identify gluten
sensitivity in DH patients [12]. Interestingly, recent data
[13] indicated that cross-linking microbial TG (mTG) may
reduce immunoreactivity of milk proteins. Cross-linking
by mTG results in integration of milk proteins epitopes
into newly created protein conglomerates, in such a way
that prevents recognition of those epitopes by speciﬁc
antibodies [13]. Beneﬁcial eﬀect of TG was also observed on
immunoreactivity modiﬁcation of cereals proteins. In this
way, it can be used to inﬂuence the clinical manifestation
of food sensitivity. Watanabe et al. [14] showed that the
use of TG allows to obtain hypoallergenic ﬂour from wheat,
which can be consumed by persons with hypersensitivity
to wheat. In light of the above, diverse roles of TGs in
immune responses are very intriguing. Poland’s national
data indicated that cross-linking by TG caused decrease
of gluten immunoreactivity [15], which raises hopes for
TG use to modify nutrition of CD/DH patients. Thus,
having knowledge of TGs is essential for understanding the
pathogenesis of CD andDH [16],in which the production of
autoantibodies to TGs (as a result of chain of events initiated
by deamidation of glutamine residue in gliadin catalyzed by
tTG) might surprisingly be of minor signiﬁcance compared
with beneﬁts resulting from TGs-mediated cross-linking of
proteins. Regardless of pathogenetical considerations, direct
immunoﬂuorescence test (DIF) of nonlesional skin remains
deﬁnitive laboratory test for diagnosing DH [7]. However,
due to numerous clinical manifestations of GSE (including
DH), the use of serological techniques becomes helpful in
clinical practice lowering the need for performing invasive
gut biopsies [17].
Receiver operating characteristic (ROC) curves represent
a relationship between sensitivity and speciﬁcity of a labora-
tory test over all possible diagnostic cutoﬀ values. So, using
ROC curves in laboratory medicine should be a common
practice to facilitate clinical decision making.
2. Aim of the Study
The aim of this study was to investigate the diagnostic
accuracy of ELISA tests evaluating serum IgA antibodies to
tTG and npG in Slavic DH patients through performing
the receiver operating characteristic (ROC) and determining
proper cutoﬀ values. Also, the aim was to assess correlations
between levels of anti-tTG and anti-npG IgA antibodies
in IgA/neutrophil-mediated DH and non-DH patients and
healthy individuals.
3.MaterialandMethods
Altogether, sera from 80 Slavic individuals were tested.
Serum samples were obtained from patients with DH (19
men and 12 women) with skin rash active enough to prompt
them to seek dermatological attention and IgA/neutrophil-
mediated non-DH dermatoses (25 patients as positive con-
trol involved 17 cases of linear IgA bullous dermatosis, 4
cases of IgA pemphigus, 3 cases of epidermolysis bullosa
acquisita and 1 case of subcorneal pustular dermatosis)
as well as from healthy individuals (negative control, 24
donors). The DH group and IgA/neutrophil-mediated non-
DH dermatoses group served as mutual control groups.
The diagnosis of DH in all cases suspected of having DH
at the clinical level was established when cutaneous IgA
deposition in any of seven possible diagnostic patterns was
seen with conventional DIF and corroborated by histological
picture with hematoxylin and eosin (H + E) staining.The Scientiﬁc World Journal 3
To distinguish from DH and establish the clinical diagnoses
ofIgA/neutrophil-mediatednon-DHdermatoses,DIFandH
+ E staining were also done. Testing of sera with biochemical
molecular techniques was done in cases requiring broader
diﬀerential diagnostics. DH serum samples were collected
during the period from February 2010 through July 2011,
and all serum samples were evaluated in the Cutaneous
HistopathologyandImmunopathologySection,Department
of Dermatology, Poznan University of Medical Sciences,
Poland. All healthy controls were not relatives of DHpatients
and gave no history of intolerance to gluten.
The levels of serum IgA autoantibodies against the
fusion protein containing nonapeptides of gliadin were
evaluated with Antigliadin (GAF-3X) ELISA (Euroimmun,
Germany) with the manufacturer’s cutoﬀ value 25RU/mL.
The levels of serum IgA autoantibodies against tTG were
assessed with Anti-tTG ELISA (Euroimmun, Germany) with
the manufacturer’s cutoﬀ value 20RU/mL. Both tests are
recommended by the producer as useful in DH diagnosis.
All measurements were made using a programmable ELISA
reader with MikroWin 2000 software by a single operator
following the manufacturer’s instructions. All tests were
performed with meticulous care to eliminate the risk of
intralaboratory errors.
Antigens which were used in the tests were obtained with
molecular engineering methods. The antigen in Antigliadin
(GAF-3X) ELISA is a recombinant fusion protein, which was
created using DNA sequences encoding gliadin-analogous
fusion peptide, GAF. These gliadin-analogous peptides con-
sist of three repeated sequences to increase the diagnostic
eﬃcacy. The created protein composition involves synthetic
nonapeptide which is gliadin analoque and nonapeptide of
digestedgliadinwhichwasdeamidatedbytransglutaminases.
Antigen in Anti-tTG ELISA is recombinant tTG. The expres-
sion of proper human cDNA was done with baculovirus
vector in insect cell systems.
In this study, the ROC analysis was used for deter-
mining cutoﬀ points for the best sensitivity and speciﬁcity
of tTG/npG ELISA tests and evaluating their ability to
discriminate disease-aﬀected from normal cases. Statistical
analysiswasperformedbyuseofMedCalcstatisticalsoftware
(http://www.medcalc.org/).Kruskal-Wallistestwithposthoc
Dunn’s test was performed to detect signiﬁcant diﬀerences
between three studied groups. Spearman’s rank correlation
coeﬃcient was computed to ﬁnd out associations between
levels of IgA antibodies to tTG and npG in all groups.
4. Results
Results of statistical analysis of three groups of examined
patients are presented in Table 1. The ROC plots created
for various combinations of examined groups are shown in
Figures 2, 3,a n d4.
The optimal cut-oﬀ for the Anti-tTG IgA ELISA
in all combinations (DH patients versus healthy con-
trol; DH patients versus IgA/neutrophil-mediated non-
DH dermatoses; combined groups) of examined groups is
17.199RU/mL (manufacturer’s cut-oﬀ is 20RU/mL). The
optimal cut-oﬀ for the Antigliadin (GAF-3X) IgA ELISA
is 24.633RU/mL in DH patients versus IgA/neutrophil-
mediated non-DH dermatoses and in combined groups
(manufacturer’s cut-oﬀ is 25RU/mL). The optimal cut-oﬀ
for the Antigliadin (GAF-3X) IgA ELISA is 24.08RU/mL in
DH patients versus healthy controls (manufacturer’s cut-oﬀ
is 25RU/mL). It is noteworthy that in each combination the
area under the ROC curve (AUC) is 1.00.
Regarding values of both anti-tTG and anti-npG IgA,
diﬀerences between healthy control and DH patients (P<
0.001) were signiﬁcant as well as between IgA/neutrophil-
mediated non-DH dermatoses and DH patients (P<
0.001), whereas diﬀerences between healthy control and
IgA/neutrophil-mediated non-DH dermatoses were not
revealed (P>0.05). The analysis of correlation showed
statistically signiﬁcant correlations between levels of IgA
antibodies to tTG and npG in both DH group (r =
0.4149) and the group of IgA/neutrophil-mediated non-
DH dermatoses (r = 0.7890), whereas there was no such
c o r r e l a t i o ni nh e a l t h yc o n t r o l s( r = 0.2231).
The following positive results were obtained in examined
groups: (i) in case of anti-tTG IgA: 90% of DH patients, 4%
of IgA/neutrophil-mediated non-DH dermatoses patients,
and 0% in healthy controls; (ii) in case of anti-npG IgA:
90% of DH patients, 8% of IgA/neutrophil-mediated non-
DH dermatoses patients, and 0% in healthy controls.
5. Discussion
InourSlavicDHpatients,theratiobetweenmenandwomen
was 1.6:1, which is consistent with the reports that DH
aﬀects men slightly more often [18, 19].
In this study, we attempt to assess diagnostic usefulness
and accuracy of tTG/npG ELISA tests in the management
of Slavic DH patients. Curiously, the research literature
data about DH and studies on its pathomechanism are
amazingly scanty in relation to the other autoimmune
blistering dermatoses, while it seems that DH pathogenesis
is far more complex. As mentioned above, GSE, both
CD and DH, is a growing medical problem, particularly
amongyoungpeople,withnutritionalimpactontheirhealth
status. Thus, speciﬁc, reliable, and objective criteria for
diagnosingandmonitoringofDHshouldbeestablished.DIF
of nonlesional skin remains a deﬁnitive laboratory test for
diagnosing this disease, however its invasiveness is a serious
limitation for screening. Indirect immunoﬂuorescence is a
time-consuming, expensive, and subjective technique; then,
ELISA seems to be free from those disadvantages. At present,
ELISA is the method of choice for serological screening of
DH. However, there is a problem what kind of ELISA-based
test is the best. The medical diagnostics market oﬀers a
wide range of ELISA kits with biotechnologically obtained
eTG, tTG, and npG as the most frequent antigen sources
for diagnosing DH. Literature data indicated that there
are discrepancies regarding the speciﬁcity and repeatability
of test results. Some ﬁndings showed that 52% of DH
patients have anti-eTG IgA elevated [20], which is consistent
with our previous study [21]. On the other hand, several
communications revealed that more than 90% of DH
patients have anti-eTG IgA elevated [19, 22]. Such divergent4 The Scientiﬁc World Journal
Table 1: Statistical analysis of the three groups of Slavic subjects studied.
IgA antibodies evaluated with Examined group Number of patients Mean SD Dunn’s test
Anti- tTG ELISA (RU/mL)
Group I 24 2.35 1.58 Group I versus group III P<0.001
Group II versus group III P<0.001
Group I versus group II P>0.05
Group II 25 13.57 46.57
Group III 31 429.20 435.23
Antigliadin (GAF-3X) ELISA
(RU/mL)
Group I 24 1.43 3.32 Group I versus group III P<0.001
Group II versus group III P<0.001
Group I versus group II P>0.05
Group II 25 15.10 44.17
Group III 30 271.00 499.25
Explanations: group I: healthy controls, group II: IgA/neutrophil-mediated non-DH dermatoses group, group III: DH patients. SD: standard deviation.
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Figure 2: ROC analysis for DH patients and healthy controls. (a) shows the plot for Anti-tTG IgA ELISA, and (b) shows Antigliadin (GAF-
3X) IgA ELISA. The cutoﬀ point marked as criterion (17.199 and 24.08, resp.).
results might be caused by evaluating series of DH patients
diﬀering in severity of cutaneous rash. In the light of this,
there is an urgent need to ﬁnd/develop a new or modiﬁed
antigen/epitope that would make the DH diagnostics more
accurate. Thus, the usefulness of tTG/npG ELISA-based tests
shouldbeconsidered.Literatureassociatedwiththisproblem
demonstrated that there is also incompatibility about the
level of anti-tTG IgA. Some investigators [20] obtained
only 25% of anti-tTG IgA-positive results in DH patients,
whereas other researchers achieved about 79% of positive
results in their patients [19, 23]. Our own experience in
this area is satisfactory: 90% of DH patients examined in
this study had anti-tTG IgA above normal range. Important
issue remains the composition and structural design of the
antigen/epitope. Byrne et al. [24] indicated that the use of
novel mutagenic variant of tTG lacking the catalytic triad
decreases the binding of IgA to the mutant tTG with the
mean reduction of 58% in DH and even bigger mean
reduction of 79% in CD samples. Fern´ andez et al. [25]
analyzed six diﬀerent human anti-tTG ELISA kits. This
group of researchers showed that there are diﬀerences in the
sensitivity and speciﬁcity of the human tTG ELISA assays.
Furthermore, they suggested that diagnostic accuracy of tests
was signiﬁcantly improved by adjusting the cutoﬀ thresholds
according to ROC curve analyses, which was done in our
study. Manufacturer’s cut-oﬀ is not standardized to each
laboratory conditions, therefore the standardization based
on ROC curve analyses should be recommended to all
ELISA tests performed for diagnostic purposes. Interestingly,
Fern´ andez et al. [25] demonstrated that the correction of
the cut-oﬀ with the use of the ROC curve analysis modiﬁes
the decision limit in more than 50% in ﬁve of the six
examined anti-human tTG ELISA kits. Hence, there is the
evidence that the way/source of production and further
modiﬁcation of antigen have the impact on test accuracy.
Researchers and diagnosticians should take it into account
before the choice of the appropriate test.
Recently [26, 27], investigators indicated the usefulness
of synthetic deamidated gliadin-derived peptides (GDR) as
antigen, which is useful for the detection ofsensitivity toThe Scientiﬁc World Journal 5
tTG
0
20
40
60
80
100
0 2 04 06 08 0 1 0 0
100-speciﬁcity
S
e
n
s
i
t
i
v
i
t
y
Sensitivity: 100, 0
Speciﬁcity: 100, 0
Criterion: > 17,199
(a)
GAF
0
20
40
60
80
100
0 2 04 06 08 0 1 0 0
100-speciﬁcity
S
e
n
s
i
t
i
v
i
t
y
Sensitivity: 100, 0
Speciﬁcity: 100, 0
Criterion: > 24,633
(b)
Figure 3: ROC analysis for all examined groups. (a) shows the plot for Anti-tTG IgA ELISA, and (b) shows Antigliadin (GAF-3X) IgA
ELISA.The cutoﬀ point marked as criterion (17.199 and 24.633, resp.).
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Figure 4: ROC analysis for DH patients and IgA/neutrophil-mediated non-DH dermatoses group. (a) shows the plot for Anti-tTG IgA
ELISA, and (b) shows Antigliadin (GAF-3X) IgA ELISA. The cutoﬀ point marked as criterion (17.199 and 24.633, resp.).
gluten in anti-tTG IgA seronegative DH patients. There
is a hypothesis that they are the most reliable tools for
identiﬁcation of gluten sensitivity in DH patients [12]. Our
study demonstrated the presence of anti-npG IgA in 90%
of examined DH patients, which may imply that usage of
the ELISA test measuring IgA antibodies to this antigen
broadens the information necessary to make the correct
diagnosis. Presented results correspond to those obtained
by Kasperkiewicz et al. [23] indicating that 84% of DH
patients have IgA to npG detected with GAF-3X ELISA. In6 The Scientiﬁc World Journal
this study, we determined the cutoﬀ value for examined
DH patients in anti-tTG ELISA as the level 17.199RU/mL
(for all examined groups), while the manufacturer’s cut-oﬀ
is 20RU/mL. In anti-npG ELISA, the cut-oﬀ for examined
population is 24.633RU/mL (for 2 combinations of groups)
and 24.08RU/mL (for DH and healthy groups), while the
manufacturer’s cut-oﬀ is 25RU/mL. Thus, there are negligi-
blediﬀerencesbetweenthem(especiallyincaseofantigliadin
GAF-3X ELISA). It can be explained by the fact that kits
usedarewellstandardizedinageneticallysimilarpopulation.
It is known that the cutoﬀ point can vary depending on
examined population, for example, diﬀerent cutoﬀ value of
anti-tTG ELISA for Italian and Spanish populations [28, 29].
Interestingly, the cutoﬀ points in our studied groups were
almostidentical.Itmaybeduetothefactthatdiseasedgroup,
IgA/neutrophil-mediated non-DH dermatoses, was chosen
as pathogenetically most closely related to DH, as far as
cutaneous pathology is concerned. Moreover, AUC obtained
i nt h i ss t u d yw a se q u a l1 ,w h i c hm a yb ed u et oap e r f e c t
separation of the values of the examined groups. It should
be stressed here that we had precise inclusion criteria and
each diagnosis had to be conﬁrmed with the combination
ofmicroscopicandbiochemical/moleculartechniques.Thus,
using the new cutoﬀ values derived from ROC curves, the
diagnostic accuracy of the tests is improved (sensitivity and
speciﬁcityof100%).Itcouldbeduetofactthatthetestswere
adapted to our native population.
There were no individuals with positive anti-tTG/npG
IgA antibodies in the healthy controls, although we did
not make the biopsy for DIF in order to rule out DH in
thesesubjectspresentingnocutaneouslesionswhatsoever.In
addition, the percentage of cases with positive anti-tTG/npG
IgA antibodies in IgA/neutrophil-mediated non-DH der-
matoses group has been quite low (4% of anti-tTG ELISA
and 8% of anti-npG ELISA). Still, it cannot be excluded that
some such cases had low-grade GST with no overt clinical
symptoms in addition to their IgA/neutrophil-mediated
non-DH dermatosis. Interestingly, ﬁndings obtained by
Ludvigsson et al. [30] in a nationwide cohort study indicated
that individuals with CD were at increased risk of psoriasis
both before and after CD diagnosis. Thus, one should be
aware that CD can coexist with other dermatoses, not only
with DH. In the light of the above, it is suggested that
recognition of anti-npG IgA alone does not mean that one
is dealing with DH as a cutaneous manifestation of GSE,
and DIF of the uninvolved skin still remains crucial for
diagnosing DH.
In our study, we demonstrated that the determination of
anti-tTG/npG IgA by means of ELISA is a precise method to
broaden the body of knowledge about DH patients in Slavic
population. However, what was noticed by Fern´ andez et al.
[25] is that it is necessary to select the ELISA kit with the
highest sensitivity and speciﬁcity and recalculate the cutoﬀ
threshold using samples from any given native population.
This sequence of actions is essential for the laboratory
diagnostician to provide reliable information to the clinician
to facilitate making right decision on the implementation of
troublesome therapy with the risk of potentially dangerous
sideeﬀects.
Statistically signiﬁcant correlation between levels of IgA
antibodies to tTG and npG in DH group (r = 0.4149) found
in this study and no such correlation in healthy controls
(r = 0.2231) might suggest that the anti-tTG and anti-
npG IgA antibodies in the IgA/neutrophil-mediated DH, but
not in healthy individuals, are produced in the coordinated
way in contrast to healthy individuals. These ﬁndings are
in agreement with our previous data [31]. This might
correspond with a suggestion that, as the catalytic site of tTG
seems to be targeted by IgA autoantibodies, intermolecular
epitope spreading from the gliadin epitopes to the catalytic
site of tTG does take place in CD [24].
In recent years, the cutaneous immunopathology of DH
h a sb e c o m et h ea r e ao fe x t e n s i v es t u d i e si nh u m a n sa n d
using animal models of the disease [21, 32, 33]. We feel that
the key issue in understanding the blister formation in DH
is not simply linking it to the GSE, but evaluating instead
localcutaneousfactors,conceivablyneutrophils’Fcreceptors
involvement, at the human skin level.
Nonetheless, it should be kept in mind, as far as the
issue of importance of npG in pathogenesis and diagnostics
of GSE is concerned, that within the gliadin peptide the
N-terminal proline residue and the C-terminal glutamine
residues were reported to be essential for antibody recogni-
tion in addition to the deamidated glutamine residue [34].
Finally, our data might suggest that Anti-tTG IgA ELISA
is marginally superior to Antigliadin (GAF-3X) IgA ELISA
for diﬀerential diagnosis of cutaneous itchy rashes suspected
to be DH at the clinical level. Plausibly, in connection
with the data that IgA1 deposits predominate in the skin
of DH suﬀerers, modiﬁcation of the above ELISA tests to
enable the determination of IgA1 subclass antibodies to tTG
a n dn p Gw o u l db ee v e nm o r ev a l u a b l ef o rd i ﬀerentiating
IgA/neutrophil-mediated dermatoses.
6. Conclusions
IgA antibodies to tTG and npG are detectable in the vast
majority of DH Slavic patients. Tests based on these antigens
tailored to native/local populations, for example, Slavic
assessed in this study, broaden DH diagnostics, being useful
for the detection of gluten sensitivity in DH. However, DIF
of the uninvolved skin still remains the reference method for
diagnosing DH.
It seems that the anti-tTG and anti-npG IgA antibodies
in the IgA/neutrophil-mediated DH, but not in healthy
individuals, are produced in the coordinated way implying
their causal relationship.
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